NYU Langone’s Laura and Isaac Perlmutter Cancer Center

Recent papers from NYU Langone’s Laura and Isaac Perlmutter Cancer Center

1. Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV MelanomaNew England Journal of Medicine · 2026
2. Geographic Disparities in Oncology Access: A National Geospatial Analysis of Workforce Distribution and Fellowship ExpansionJCO Oncology Practice · 2026
3. Dosimetric impact of MRI and PSMA-PET discordance in intraprostatic boost planning for high-risk prostate cancerRadiation Oncology · 2026
4. Access to clinical cancer genomics and precision oncology-based care in North AmericaThe Lancet Regional Health - Americas · 2026
5. Liquid biopsy for brain tumorsCurrent Opinion in Neurology · 2026
6. The rise of reducing reagent-resistant TfR1 dimer marks ferroptosisNature Cell Biology · 2026
7. Cancer vaccines and the future of immunotherapyThe Lancet · 2025
8. Sugar-rich foods exacerbate antibiotic-induced microbiome disruptionNature · 2026
9. Type 2 immune history trains lung macrophages for viral disease toleranceNature · 2026
10. Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025Cancer · 2026
11. Real‐world outcomes of nivolumab‐ AVD and brentuximab vedotin‐ AVD in paediatric and adult advanced‐stage Hodgkin lymphomaBritish Journal of Haematology · 2026
12. Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemiaBlood Cancer Journal · 2026
13. Spatial mixed models for assessing environmental exposure effects on the microbiomeGenome Medicine · 2026
14. Sex-associated miR-4286 is related to Breslow thickness and TILs in stage II/III primary cutaneous melanoma2026
15. Natural language processing-based model to predict radiation pneumonitis in patients with locally advanced non-small cell lung cancer undergoing chemoradiotherapy: a retrospective cohort studyEClinicalMedicine · 2026
16. CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancerCell · 2026
17. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancerNature Medicine · 2026
18. Pan-cancer proteogenomic interrogation of the ubiquitin-proteasome systemCell Death and Differentiation · 2026
19. Integrated Interactomics Reveals Novel Protein Associations: The FOXA1-PBX1 Complex as a Case Study2026
20. Epigenetic Reactivation of Lineage Differentiation to Target Leukemia2026